


The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5311
Facsimile: 703-243-6410
Email: zelano@mwzb.com

AJZ:kmo

FILED: 15 JANUARY 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE:

Claims 3, 4, 7 and 8 were amended as follows:

3. (Amended) Peptide compounds according to Claim 1 ~~or~~ 2 selected from the group consisting of
- cyclo (Arg-Gly-Asp-Leu-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
 - cyclo (Arg-Gly-Asp-Leu-Asp-Gly-Leu-Arg-Gly-Gly-Gly),
 - cyclo (Arg-Gly-Asp-Leu-D-Ala-Ala-Leu-Arg-Gly-Gly-Gly),
 - cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
 - cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
 - cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha-Aha),
 - cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha),
 - cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aee),
 - cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
 - cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg- β -Ala),
 - cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg- β -Ala),
- and their physiologically acceptable salts and solvates.
-

4. (Amended) Peptide compounds of the formula I according to Claims 1 and 2 and the compounds according to Claim 3, selected from the group consisting of

cyclo (Arg-Gly-Asp-Leu-Asp-Ala-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Gly-Asp-Leu-Asp-Gly-Leu-Arg-Gly-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Gly-Asp-Leu-D-Ala-Ala-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha-Aha),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aee),

cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),

cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg- β -Ala),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg- β -Ala),

and their physiologically acceptable salts and solvates, as medicaments.

7. (Amended) Pharmaceutical preparation, comprising at least one medicament according to one of Claims 5 and 6 and, if appropriate, vehicles and/or excipients and, if appropriate, other active compounds.

8. (Amended) Use of peptide compounds according to Claims 1 to 3 and/or their physiologically acceptable salts for producing a medicament for the control of disorders which are based on expression and pathological function of $\alpha_v\beta_6$ integrin receptors.